Globally, stomach cancer ranks as the fifth most common cancer and is responsible for the fifth leading cause of cancer-related deaths. According to the International Agency for Research on Cancer, ...
The European Commission approved Tevimbra, the commercial name for Tislelizumab, in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or ...